Building a true strategy about your pharmaceutical drugability
Years of experience
Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Drugabilis will attend the 11th hybrid-format of BioFit 2022 hold in-person in Strasbourg on November 29th-30th. It will be a perfect opportunity to meet with worldwide academics, TTOs and research...